ArticleCancer reports (Hoboken, N.J.)2026
Incidence of Second Malignancies Among Children Treated for Cancer With Radiotherapy in Egypt.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Assessment of Health Status in Populations Living in the Semipalatinsk Nuclear Test Site Region: Results of Screening.Healthcare (Basel, Switzerland) · 2026Article
- Incidence of Second Malignancies Among Children Treated for Cancer With Radiotherapy in Egypt.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSurvivors of childhood cancer (CCS) are at risk for secondary malignant neoplasms (SMNs): serious late effects of treatment. Radiotherapy (RT) and chemotherapy (CT) are possible causes of SMNs.
aimsTo measure SMN incidence and characteristics among Egyptian CCS treated with RT, and to compare SMN timing and location based on RT field and CT type. METHODS AND
resultsWe performed a retrospective cohort study of patients under 18 years who received radiotherapy for primary cancer at the Children's Cancer Hospital, Cairo, Egypt, from 2009 to 2015, with follow-up through 2021. We calculated cumulative incidence functions for second malignant neoplasm (SMN) development overall and by primary diagnosis, using the Fine and Gray method, both for all SMNs and for in-field SMNs. We used the Wilcoxon rank-sum test to compare time to SMN between patients with in-field versus out-of-field SMNs and those who received alkylating versus non-alkylating chemotherapy. Of 3132 patients (60.1% male; median age 6.2 years), 23 developed an SMN (11.1-year cumulative incidence: 1.85%, 95% CI: 0.84%-3.57%). Eight (34.8%) of the 23 SMNs arose within the prior RT field (11-year cumulative incidence: 2.71%, 95% CI: 1.32%-4.93%). Median time to SMN was longer for in-field than out-of-field cases (7.9, IQR: 6.0-9.9 vs. 4.3 years, IQR: 2.7-5.6; p = 0.002). There was no significant difference in time to SMN by CT type.
conclusionSMN incidence in this cohort matched rates in high-income countries. Strong long-term follow-up is essential for CCS in Egypt and similar settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.